- Home
- SRTS vs CTOR Comparison
SRTS vs CTOR Comparison
Compare SRTS & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- CTOR
- Stock Information
- Founded
- SRTS 2010
- CTOR 2021
- Country
- SRTS United States
- CTOR United States
- Employees
- SRTS N/A
- CTOR N/A
- Industry
- SRTS Medical/Dental Instruments
- CTOR
- Sector
- SRTS Health Care
- CTOR
- Exchange
- SRTS Nasdaq
- CTOR NYSE
- Market Cap
- SRTS 106.0M
- CTOR 89.9M
- IPO Year
- SRTS 2016
- CTOR N/A
- Fundamental
- Price
- SRTS $8.89
- CTOR $0.87
- Analyst Decision
- SRTS Strong Buy
- CTOR Strong Buy
- Analyst Count
- SRTS 2
- CTOR 1
- Target Price
- SRTS $12.50
- CTOR $6.00
- AVG Volume (30 Days)
- SRTS 262.3K
- CTOR 86.4K
- Earning Date
- SRTS 11-14-2024
- CTOR 12-03-2024
- Dividend Yield
- SRTS N/A
- CTOR N/A
- EPS Growth
- SRTS N/A
- CTOR N/A
- EPS
- SRTS 0.57
- CTOR N/A
- Revenue
- SRTS $41,308,000.00
- CTOR N/A
- Revenue This Year
- SRTS $55.14
- CTOR N/A
- Revenue Next Year
- SRTS $21.75
- CTOR N/A
- P/E Ratio
- SRTS $15.62
- CTOR N/A
- Revenue Growth
- SRTS 65.62
- CTOR N/A
- 52 Week Low
- SRTS $2.05
- CTOR $0.85
- 52 Week High
- SRTS $9.20
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- SRTS 75.94
- CTOR N/A
- Support Level
- SRTS $6.70
- CTOR N/A
- Resistance Level
- SRTS $9.20
- CTOR N/A
- Average True Range (ATR)
- SRTS 0.56
- CTOR 0.00
- MACD
- SRTS 0.21
- CTOR 0.00
- Stochastic Oscillator
- SRTS 89.08
- CTOR 0.00
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.